CJC-1295 + Ipamorelin is a growth peptides research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
The CJC-1295 / Ipamorelin combination is the most widely studied GH secretagogue co-administration protocol in preclinical research. The two compounds act at distinct, mechanistically complementary receptors: CJC-1295 (modified GRF 1-29) targets the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, while Ipamorelin targets the ghrelin receptor (GHS-R1a) at both pituitary and hypothalamic levels. Simultaneous engagement of both receptor systems produces synergistic GH pulse amplification that exceeds what either agent achieves alone — a well-characterized finding in rodent pituitary research models.
Research interest in this combination centers on the mechanistic synergy between GHRHR and GHS-R1a pathways. At the cellular level, GHRHR signals via Gs-cAMP-PKA, while GHS-R1a signals via Gq-PLC-PKC; dual activation of both pathways within the same somatotroph cell is hypothesized to produce multiplicative rather than additive GH exocytosis. Ipamorelin's selectivity profile — high GH specificity with minimal cortisol, prolactin, or FSH stimulation at research doses — makes it a preferred GHS-R1a agonist for combination protocols where minimizing off-target secretagogue effects is important.
PeptidesFromChina.co supplies CJC-1295 (without DAC) and Ipamorelin as separate lyophilized powders, allowing custom ratio formulation, as well as pre-combined vials for standardized research protocols. Both components are at 99%+ purity, verified by HPLC and Mass Spectrometry. All products are for laboratory research use only and are not for human consumption.
| Combination Components | CJC-1295 without DAC (Modified GRF 1-29) + Ipamorelin |
|---|---|
| Receptor Targets | GHRHR (CJC-1295) + GHS-R1a (Ipamorelin) |
| Signaling Pathways | Gs-cAMP-PKA (GHRHR) + Gq-PLC-PKC (GHS-R1a) |
| Research Areas | GH axis pharmacology, pituitary synergy research, GH pulse architecture, IGF-1 regulation |
| Administration Form | Separate lyophilized powders or pre-combined vials |
| Storage | −20°C long-term; 2-8°C aqueous (use within 2 weeks) |
| CAS Number | N/A — combination product |
| Molecular Weight | N/A — see individual component COAs |
| Molecular Formula | N/A — combination product |
| Sequence | N/A — combination product |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| CJC-1295 Without DAC 5mg + Ipamorelin 5mg | 10 mg | 10 vials | ≥98% | In Stock | $107.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis (COA) is included with every order. Documentation covers purity, molecular weight, and batch identification.
The central research question for the CJC-1295/Ipamorelin combination is whether dual pathway engagement at GHRHR and GHS-R1a produces additive or synergistic GH release. Studies in rodent pituitary cell cultures and intact animal models have documented GH peak concentrations exceeding the sum of individual compound effects — consistent with a synergistic interaction between cAMP and PLC signaling cascades within somatotroph cells. This synergy is a model system for studying receptor crosstalk in endocrine pharmacology.
Research has characterized the GH pulse profiles produced by the combination versus each agent alone, examining peak amplitude, pulse duration, and inter-pulse interval. CJC-1295's 30-minute half-life produces a defined stimulation window, while Ipamorelin's GHS-R1a activity amplifies the somatotroph response within that window. This defined pharmacokinetic-pharmacodynamic relationship makes the combination a useful tool for studying GH pulse physiology under controlled conditions.
In vivo rodent research has examined downstream IGF-1 responses following CJC-1295/Ipamorelin co-administration, including hepatic IGF-1 production, circulating IGF-1 concentrations, and IGF-1-responsive tissue endpoints. The combination's ability to produce consistent GH pulses in aged rodent models — where endogenous GH secretion is blunted — has made it a tool for studying GH axis restoration and IGF-1 dynamics in aging research.
The two compounds engage different receptors with different intracellular signaling mechanisms. When both are active simultaneously in the same pituitary somatotroph, the combined cAMP (GHRHR) and PLC (GHS-R1a) signaling produces synergistic GH release beyond what either alone achieves. This synergy is documented in rodent models and is the primary reason the combination is used in GH axis research protocols.
Both options are available. Pre-combined vials allow standardized dosing in research protocols. Separate vials of CJC-1295 (without DAC) and Ipamorelin allow custom ratio formulation. Contact us via the Request page for wholesale pricing on both formats.
Both CJC-1295 (without DAC) and Ipamorelin are synthesized to 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis from the manufacturing facilities is included with every batch.
CJC-1295 without DAC (used in this combination) has a ~30-minute half-life, producing acute GH pulses. CJC-1295 with DAC has a 6-10 day half-life via albumin binding, producing sustained GHRHR stimulation. The combination protocol uses the short-acting form to produce discrete, pulse-like GH stimulation synergized by Ipamorelin.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.